التفاصيل البيبلوغرافية
| العنوان: |
Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. |
| المؤلفون: |
Strickler, John H, Cubillo, Antonio, Liang, Jin-Tung, Matrana, Marc, Kozloff, Mark, Lowe, Thomas, Blaney, Martha, Sahtout, Mohammad, Naumovski, Louie, Wainberg, Zev A |
| المصدر: |
Future Oncology; Sep2022, Vol. 18 Issue 27, p3011-3020, 10p |
| مصطلحات موضوعية: |
THERAPEUTIC use of antineoplastic agents, COLON tumors, FOLINIC acid, RESEARCH, CLINICAL trials, RECTUM tumors, RESEARCH methodology, CAMPTOTHECIN, ANTINEOPLASTIC agents, PROGNOSIS, EVALUATION research, COLORECTAL cancer, FLUOROURACIL, COMPARATIVE studies, RESEARCH funding |
| مستخلص: |
Aim: This phase II study investigated safety and efficacy of dilpacimab or bevacizumab plus FOLFIRI in patients with previously treated metastatic colorectal cancer (mCRC). Materials & methods: Overall, 66 patients were treated (n = 34 dilpacimab + FOLFIRI; n = 32 bevacizumab + FOLFIRI). Progression-free survival, overall survival, response rates and tolerability were assessed. Results: Median progression-free survival for dilpacimab + FOLFIRI compared with bevacizumab + FOLFIRI was 3.78 months (95% CI: 2.07-7.20) versus 7.36 months (95% CI: 5.68-10.55) (hazard ratio: 3.57; 95% CI: 1.57-8.11; stratified). Median overall survival: 7.95 months for dilpacimab + FOLFIRI; not reached for bevacizumab + FOLFIRI. Objective response rates: 5.6% for dilpacimab + FOLFIRI and 14.7% for bevacizumab + FOLFIRI. Patients treated with dilpacimab + FOLFIRI experienced serious treatment-related adverse events (n = 4; 11.8%), including one case of intestinal perforation leading to death; none were reported for bevacizumab + FOLFIRI. Conclusion: Treatment with dilpacimab + FOLFIRI was not well tolerated and did not provide clinical benefit to patients with mCRC compared with bevacizumab + FOLFIRI. Clinical Trial Registration: NCT03368859 (Clinicaltrials.gov). [ABSTRACT FROM AUTHOR] |
|
Copyright of Future Oncology is the property of Future Medicine Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
